Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Extended endocrine treatment"'
Autor:
Giuseppe Buono, Grazia Arpino, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Fabio Puglisi, Alberto Zambelli, Saverio Cinieri, Francesco Nuzzo, Vincenzo Di Lauro, Paolo Vigneri, Giampaolo Bianchini, Filippo Montemurro, Alessandra Gennari, Michelino De Laurentiis
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The use of an aromatase inhibitor (AI) in combination with ovarian function suppression (OFS) has become the mainstay of adjuvant endocrine therapy in high-risk premenopausal patients with hormone receptor-positive breast cancer. Although five years
Externí odkaz:
https://doaj.org/article/f86a16dbeaf742f49f08d47e23dabb79
Autor:
Li Li, Bingmei Chang, Xiaoyue Jiang, Xueke Fan, Yingrui Li, Teng Li, Shanshan Wu, Jun Zhang, Seyed Kariminia, Qin Li
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Adjuvant endocrine therapy undoubtedly prolongs the time to recurrence for patients with hormone-positive early breast cancer. Extended endocrine therapy to 10 years or longer has been expected to bring a greater clinical advantag
Externí odkaz:
https://doaj.org/article/dfa9858efddf43b18bfc081d1f1123b2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yingrui Li, Bingmei Chang, Jun Zhang, Xueke Fan, Li Li, Shanshan Wu, Xiaoyue Jiang, Qin Li, Teng Li, Seyed Kariminia
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Background Adjuvant endocrine therapy undoubtedly prolongs the time to recurrence for patients with hormone-positive early breast cancer. Extended endocrine therapy to 10 years or longer has been expected to bring a greater clinical advantage. Howeve